- Home
- PSHG vs BCTX Comparison
PSHG vs BCTX Comparison
Compare PSHG & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSHG | BCTX |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | Greece | Canada |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.9M | 18.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PSHG | BCTX |
|---|---|---|
| Price | $2.25 | $9.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | ★ 172.0K | 55.2K |
| Earning Date | 11-25-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $79,691,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $33.79 | $380.95 |
| P/E Ratio | $1.76 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.31 | $6.00 |
| 52 Week High | $2.58 | $106.50 |
Technical Indicators
Market Signals| Indicator | PSHG | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.67 | 44.95 |
| Support Level | $1.97 | $11.38 |
| Resistance Level | $2.43 | $13.09 |
| Average True Range (ATR) | 0.15 | 1.14 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 52.46 | 30.12 |
Price Performance
Historical ComparisonAbout PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.